Weekly RSV Vaccination Dashboard

Adults 50+ RSV Vaccination Coverage

RSV vaccination coverage estimates among adults 75 years and older and 50─74 years with high-risk conditions for RSV are based on self-reported data from CDC’s National Immunization Survey-Fall Respiratory Virus Module (FRVM), which are based on self-report. Data and charts are available.

As of November 22, 2025, among adults 75 years and older:

• An estimated 39.8% (95% Confidence Interval: 37.2%─42.4%) reported having ever received an RSV vaccine.
  • An additional 7.7% (4.5%─10.8%) reported they definitely will get a vaccine.

• Vaccination coverage varied by health insurance status, poverty status, race and ethnicity, sex, urbanicity, and presence of a chronic medical condition.

As of November 22, 2025, among adults 50─74 years with a high-risk condition for RSV:

• An estimated 30.7% (27.5%─33.9%) reported having ever received an RSV vaccine.
  • An additional 13.7% (10.1%─17.4%) reported they definitely will get a vaccine.

• Vaccination coverage varied by age, health insurance status, and poverty status.

Adults 75+ RSV Vaccination Administration and Coverage (monthly)

The summaries for the 2025─26 season will be populated as the data become available throughout the fall/Winter.

Adults 75+ RSV Vaccination Coverage (monthly)

RSV vaccination coverage among Medicare fee-for-service beneficiaries 75 years and older and enrolled in a Part D plan is assessed using data files from the Medicare Fee-For-Service administrative claims data managed by the Centers for Medicare & Medicaid Services. Data and charts are available.

• As of September 27, 2025, an estimated 34.4% of Medicare fee-for-service beneficiaries 75 years and older enrolled in a Part D plan were vaccinated.
• Vaccination coverage was highest among White, non-Hispanic beneficiaries (35.3%) and lowest among Hispanic beneficiaries (13.1%).

RSV Vaccinations Administered in Pharmacies and Medical Offices (IQVIA)

IQVIA measures RSV vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians’ medical offices for all adults 50 years and older (regardless of presence of high-risk conditions for RSV), based on healthcare claims data. Data and charts are available.

During August 12, 2023, through November 8, 2025, in retail pharmacies and physicians’ medical offices combined:

• An estimated ~210,184 doses of RSV vaccines were administered among all adults 50-59 years.
• An estimated ~9.09 million doses of RSV vaccines were administered among all adults 60-74 years.
• An estimated ~7.10 million doses of RSV vaccines were administered among all adults 75 years and older.

Pregnant Women RSV Vaccination Coverage

The summaries for the 2025─26 season will be populated as the data become available throughout the fall/Winter.

Monoclonal Antibody Coverage and Intent for Infants (monthly)

Monthly estimates of infant protection against RSV by maternal RSV vaccination or receipt of monoclonal antibody, as well as intent for monoclonal antibody receipt, reported by females 18─49 years with infants <8 months during the RSV season (born since April 1, 2025) are based on data from CDC’s National Immunization Survey-Fall Respiratory Virus Module (FRVM). Data and charts are available.

• As of October 2025, among females with an infant born since April 1, 39.6% of infants were reported to be protected against RSV through either maternal immunization only (3.3%) or receipt of monoclonal antibody (36.3%); an additional 16.9% reported that they would definitely get monoclonal antibody for their infants.

Nirsevimab Administration and Coverage for Infants (monthly)

The summaries for the 2025─26 season will be populated as the data become available throughout the fall/Winter.